Lexapro delivers results for Lundbeck  

Promising clinical research data boosts Lundbeck's bid to make Lexapro a world beater

Hot on the heels of Lundbeck's announcement of a massive worldwide marketing drive for its new SSRI antidepressant treatment Lexapro (Cipralex in Europe), comes promising news from clinical quarters. Results from a study presented at the 15th Congress of the European College of Neuropsychopharmacology show that the drug works faster and is better tolerated than the competitor drug Effexor (venlafaxine). An article in Jyllands-Posten quotes Nordea Securities as saying that new study "strengthens the belief that Lundbeck has a good product".


Over the next 5 years, Lundbeck is reportedly investing more than DKK 1 billion (USD 130 million) each year to globally market Lexapro (escitalopram). The company recently struck a deal with Abbott Laboratories to market, sell and distribute Lexapro in all Latin American markets. A similar alliance is expected for the Asian market. The marketing initiative is described as one of biggest ever undertaken by a Danish company, and if successful will make Lundbeck one of Denmark's largest concerns.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×